Faun Pharma reaches new revenue record for October
The revenue of Zinzino AB:s (publ.) production facility Faun Pharma in Norway continues to increase. Through a determined work with quality management and good investments the production facility in Norway shows an increase in revenue by 4.8 million SEK in October, compared with the same period previous year.
Faun Pharmas shows an increase in revenue by 4.8 million SEK in October, compared with the same period previous year. The revenue in total for October is 10.1 million SEK and an order stock of over 30 million SEK. Internal sales with Zinzino was 1.6 million SEK of the 10.1 million SEK.
-We are starting to see the effects of our strategic work, quality management and our ISO9001 certification. We have also invested in our personal, machine and equipment and in October we introduced two shifts production. Two new companies Orkla and Norsk Medisinaldepot have started test production in our factory. Both companies have a great potential for Faun Pharma says Erlend Strømnes, MD Faun Pharma.
Earlier this year Faun Pharma got the contract for all of Proteinfabrikkens production. A three-year contract was signed with a total value of over 30 Million SEK and a production increase of 500-600 ton. The forecast shows that Faun Pharma will continue to grow and several new projects have started to optimize and automate the production and the production rate
- The strong sales numbers are an important prequisition to reach our financial goal which includes a revenue between 470 million SEK and 520 million SEK 2016. Our focus continues to be quality and development of new products and to reach our goal of a sales increase of at least 20% during the period 2016 to 2018, says Dag Bergheim Pettersen, CEO Zinzino.
INFORMATION ABOUT THE COMPANY: Zinzino was founded under the name Zinzino Holding in autumn 2007. In 2009, the company acquired 93% of the equity and 97% of the votes in Zinzino Nordic AB, partly by means of a non-cash issue and partly by means of a private placement. Zinzino Nordic is a sales company that uses independent distributors to market and sell products for commission via so-called direct sales.
For more information, please contact:
Dag Bergheim Pettersen, CEO of Zinzino, Tel. no.: +47(0) 93 22 57 00
For free to publish pictures, please contact: Lars Dahlberg, tfn + 46 (0) 70-779 77 70
Certified Adviser: Erik Penser Bank
www.zinzino.se
The information presented here is such that Zinzino AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, 3.30 PM on November 4, 2016.
Zinzino Nordic AB (publ.) Is a direct sales company that operates throughout the EU, Norway, Iceland and North America. Zinzino markets and sells products in two product lines; Zinzino Health, with a focus on long-term health, and Zinzino Coffee, consisting of espresso machines, coffee, tea and accessories. Zinzino owns the Norwegian knowledge-based company BioActive Foods AS and the research and production unit Faun Pharma AS. Today Zinzino have some 100 employees in the Group. The company has its headquarters in Gothenburg, and has offices in Helsinki, Riga, and in Florida, USA. Zinzino is a public company and its shares are listed on Nasdaq First North. Zinzino is one of Swedish financial magazine Veckans Affärer’s “Super Company 2015” and one of the winners of the award “Gazelle 2013” in the Swedish financial magazine “Dagens Industri”.
Tags: